1
|
Sandoval ML, Rishi A, Liveringhouse C, Dohm AE, Palm RF, Perez BA, Frakes JM, Rosenberg SA, Hoffe S, Dilling TJ. Outcomes of Cytoreductive Stereotactic Body Radiotherapy (SBRT) in Patients with Oligometastatic or Oligoprogressive Dominant Lung Metastases from Colorectal Primary. Int J Radiat Oncol Biol Phys 2023; 117:e53. [PMID: 37785644 DOI: 10.1016/j.ijrobp.2023.06.764] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Oxaliplatin based systemic therapy regimens have improved the prognosis of patients with colorectal cancer (CRC) and with this, there has been increased interest in the integration of local therapies to oligometastatic and oligoprogressive sites. There is a vast body of literature exploring the benefits of cytoreduction with surgery and stereotactic body radiation therapy (SBRT) approaches. We report our rates of local control (LC) and overall survival (OS) for patients with oligometastatic/progressive CRC with lung metastases treated with SBRT. MATERIALS/METHODS Single institution retrospective review of patients diagnosed with oligometastatic or oligoprogressive CRC with dominant metastases to the lungs who were treated with SBRT between September 2009 and December 2022. Oligometastatic disease was defined as newly diagnosed, untreated CRC with up to 5 metastases, up to 3 in one organ. Oligoprogressive disease was defined as CRC with 1 - 2 distant sites that continued to progress on active treatment while the primary site was controlled. Survival was estimated using Kaplan-Meier. Association between local control and patient factors was analyzed using log-rank test. RESULTS A total of 84 patients with oligometastatic or oligoprogressive CRC were treated with SBRT to 124 lung lesions. Colon cancer was the primary site for 54 patients with a median age at time of SBRT of 66 years (IQR 57 - 73) and a median tumor diameter of 1.20 cm (IQR 0.93 - 1.90). Rectal cancer was the primary site for 30 patients, median age was 60 years (IQR 49 - 70) and median tumor diameter was 1.10 cm (IQR 0.80 - 1.48). Median dose for the entire cohort was 6000 cGy (range 5000 - 6000) with median number of fractions 5 (range 3 - 5). Median follow-up after SBRT was 24 months. Overall, there were 9 local failures at last follow-up. Almost half (n = 42) of the patients experienced distant recurrence. Median local control (LC) for the entire cohort was not reached, 2-yr LC and 5-yr LC were 94.6% and 85.7% respectively. There were no differences in LC between colon and rectal cancer (p = 0.29). Actuarial median overall survival was 71 months (95% CI 44.3 - 97.7) and 5-yr OS was 50.2%. Due to the small number of events, we were unable to identify patient factors associated with local failure on univariate or multivariate analysis. CONCLUSION Cytoreductive SBRT is an effective treatment option for patients with oligometastatic or oligoprogressive CRC with dominant lung metastases offering excellent rates of LC. Most patients failed distantly highlighting the importance of additional systemic therapies.
Collapse
Affiliation(s)
- M L Sandoval
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - A Rishi
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - C Liveringhouse
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - A E Dohm
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - R F Palm
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - B A Perez
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - J M Frakes
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - S A Rosenberg
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - S Hoffe
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - T J Dilling
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| |
Collapse
|
2
|
Dohm AE, Upadhyay R, Tang JD, Oliver DE, Perez BA, Rosenberg SA, Yu HHM, Palmer JD, Beyer S, Owen D, Ahmed KA. Upfront Osimertinib Alone vs. Osimertinib and Radiotherapy for the Treatment of EGFR-Positive NSCLC Brain Metastases: A Multi-Institutional Series. Int J Radiat Oncol Biol Phys 2023; 117:e100-e101. [PMID: 37784626 DOI: 10.1016/j.ijrobp.2023.06.869] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Given the increased brain penetrance of osimertinib, the role of upfront radiotherapy (RT) has been questioned for the management of patients with EGFR+ NSCLC brain metastases (BM). We conducted a multi-institutional review of patients with EGFR+ NSCLC treated with upfront osimertinib or osimertinib in combination with RT for new or progressing BM. MATERIALS/METHODS Our multi-institutional analysis included 128 patients with 714 BM treated between 2013 and 2022. Two BM treatment groups were evaluated: (1) upfront osimertinib alone (n = 66) and (2) osimertinib + RT [whole brain radiation therapy or stereotactic/fractionated radiosurgery (SRS/FSRT)] prior or concurrently with osimertinib (n = 62)]; both groups began treatment within 2 months of BM diagnosis. Time-to-event analysis was conducted with the Kaplan-Meier (KM) method, and outcomes included intracranial control (IC) [both local and distant], intracranial progression free survival (IPFS), and overall survival (OS). A Cox proportional hazards model was utilized for multivariate analysis (MVA). RESULTS Median follow-up from BM diagnosis was 33.9 months (0.13-76.2 months). No differences in age (p = 0.46), sex (p = 0.72), DS-GPA (p = 0.08), KPS (p = 0.57), number of BM (p = 0.19) or volume of BM (p = 0.45), RT dose (p = 0.45), number of systemic metastases (p = 0.88), and patients symptomatic at presentation (p = 1.0) were noted. Prior treatment of BM was more common in the osimertinib + RT group (50% osimertinib + RT and 27% osimertinib; p = 0.01). The 12-month KM rates for osimertinib vs osimertinib + RT groups for IC were 72% vs 73% (p = 0.33); IPFS 53% vs 66% (p = 0.007); and OS 65% vs 80% (p = 0.025). On MVA, higher KPS (p = 0.002) was associated with increased OS and no extracranial metastasis with increased OS (p = 0.01) and IPFS (p = 0.001). MVA showed no association between osimertinib vs osimertinib + RT for IC, IPFS, or OS. Of the 66 patients treated with upfront osimertinib, 18 patients (27%) with 31 lesions eventually required RT for intracranial progression with the majority 72% being treated with SRS/FSRT at median of 13.5 months (1-22 months) following the start of osimertinib. CONCLUSION This study suggests that upfront osimertinib alone may provide sufficient intracranial control to allow RT to be deferred until further intracranial progression in select patients. Prospective trials are warranted to further guide treatment.
Collapse
Affiliation(s)
- A E Dohm
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - R Upadhyay
- The Ohio State University Wexner Medical Center, Columbus, OH
| | - J D Tang
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - D E Oliver
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - B A Perez
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - S A Rosenberg
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - H H M Yu
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - J D Palmer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - S Beyer
- Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, OH
| | - D Owen
- The Ohio State University, Columbus, OH
| | - K A Ahmed
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| |
Collapse
|
3
|
Retzloff A, Li R, Gilbert SM, Dohm AE, Sexton WJ, Poch M, Zemp LW, Pow-Sang J, Jain R, Chatwal MS, Dhillon J, Yamoah K, Fernandez DC, Johnstone PAS, Spiess P, Grass D. Multidisciplinary Management of Primary Urethral Cancer with Radiotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e431-e432. [PMID: 37785408 DOI: 10.1016/j.ijrobp.2023.06.1597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Primary urethral cancer (PUC) is a rare form of genitourinary malignancy with a paucity of data to guide management. We analyzed PUC patients for clinicopathologic characteristics and treatment approach (radiotherapy [RT] with/without consolidative surgery) to identify predictors of outcome and RT response. MATERIALS/METHODS We conducted a single-institution retrospective review of patients treated with RT for PUC between 2002 to 2020. Each patient underwent multidisciplinary evaluation (including cystoscopy) as well as imaging to confirm tumor origin in the urethra. The linear quadratic formula was used to calculate the biologically effective dose (BED) using an α/β of 10 for tumor. Descriptive statistics were used to characterize the cohort. Fisher's Exact test was used to compare groups. Time-to-event analyses was conducted with the Kaplan-Meier method; outcomes included overall survival (OS) and time to recurrence (TTR) from diagnosis. Cox regression analysis assessed predictors of outcomes. RESULTS A total of 17 patients were identified for analysis. Median age was 63 years (range: 34-86); the majority were female (76.5%) and white (82.4%). Tumors were localized in the proximal (n = 6) or distal (n = 11) urethra. Histology included urothelial (11.8%), squamous (35.3%), adenocarcinoma (29.4%) and mixed (23.5%). Ten patients (58.8%) had cT3 or higher disease with 10 being cN0 (58.8%), 1 cN1 (5.9%), 5 cN2 (29.4%) and 1 cNx (5.9%). Median tumor size was 4.8 cm (range: 0.5-12 cm). The majority (88.2%) were treated with definitive chemoRT with 70.5% receiving platinum therapy. Median RT dose was 59.4 Gy (range: 39.6-70.2) with a median of 30 fractions. One patient underwent upfront cystourethrectomy and 6 (35.3%) underwent consolidative surgery at a median of 2.3 months after RT. Five patients (29.4%) had a complete response (CR) and 70.6% had a partial response (PR) to RT. Of the 7 patients who underwent surgical resection the final pathology was ypTis (28.5%), ypT1 (14.2%), ypT2 (14.2%), ypT4 (28.5%) and pT2 (14.2%). A median of 16 lymph nodes were removed with 1 patient having pN2 and all others pN0. Four patients (66.6%) were downstaged by chemoRT prior to surgery. At a median follow-up time of 8.4 years, the median OS was 37.9 months (range: 23.2-52.7), which was associated with a 5-year OS of 37.2%. Twelve (70.5%) patients recurred with a median TTR of 6.3 months (range 4.8-7.7). No demographics, staging methods, or tumor characteristics were associated with OS or TTR. Urothelial histology was associated with CR following chemoRT (p = 0.02). RT dose (continuous) was associated with OS (p = 0.018) as well as a BED (HR: 0.90, 95% CI: 0.84-0.97; p = 0.01). A BED > 55 Gy was associated with improved median OS (56.4 vs 9.13 months, p = 0.006). CONCLUSION Analysis of PUC patients treated with multimodal therapy found higher rates of CR in patients with urothelial histology and increased OS in patients treated with a BED > 55 Gy. Neoadjuvant chemoRT may downstage disease prior to surgical extirpation.
Collapse
Affiliation(s)
- A Retzloff
- USF Health Morsani College of Medicine, Tampa, FL
| | - R Li
- H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Oncology, Tampa, FL
| | - S M Gilbert
- H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Oncology, Tampa, FL
| | - A E Dohm
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - W J Sexton
- H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Oncology, Tampa, FL
| | - M Poch
- H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Oncology, Tampa, FL
| | - L W Zemp
- H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Oncology, Tampa, FL
| | - J Pow-Sang
- H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Oncology, Tampa, FL
| | - R Jain
- H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Oncology, Tampa, FL
| | - M S Chatwal
- H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Oncology, Tampa, FL
| | - J Dhillon
- H. Lee Moffitt Cancer Center and Research Institute, Department of Anatomic Pathology, Tampa, FL
| | - K Yamoah
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - D C Fernandez
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - P A S Johnstone
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| | - P Spiess
- H. Lee Moffitt Cancer Center and Research Institute, Department of Genitourinary Oncology, Tampa, FL
| | - D Grass
- H. Lee Moffitt Cancer Center and Research Institute, Department of Radiation Oncology, Tampa, FL
| |
Collapse
|